Following a successful pre-BLA meeting with the FDA, Iovance stated it is pursuing accelerated approval in this indication. "Completing our BLA submission for lifileucel is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor. I would like to acknowledge the patients and physicians who participated in the C-144-01 clinical trial and the FDA review team for their commitment and support, as well as our internal team for their tremendous effort in completing the first BLA submission for Iovance," Frederick Vogt, PhD, JD, Interim President and Chief Executive Officer of Iovance, said in a company news release. "Our preparations for commercialization remain on track to support a launch later this year. We look forward to continued collaboration with the FDA as they review this new class of treatment for advanced melanoma patients with limited options."